Meanwhile, novel antibody-based agents (e.g., anti-DLL3/4 antibodies) and bispecific T-cell engagers (e.g., AMG 119) show promise in T-ALL and small cell lung cancer (SCLC), yet encounter challenges due to vascular toxicity caused by insufficient receptor/ligand selectivity (107). The gene discussed is DLL3; the disease is small cell lung carcinoma.